<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CPR</journal-id>
<journal-id journal-id-type="hwp">spcpr</journal-id>
<journal-id journal-id-type="nlm-ta">Eur J Cardiovasc Prev Rehabil</journal-id>
<journal-title>European Journal of Preventive Cardiology</journal-title>
<issn pub-type="ppub">2047-4873</issn>
<issn pub-type="epub">2047-4881</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1741826711422990</article-id>
<article-id pub-id-type="publisher-id">10.1177_1741826711422990</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Rehabilitation</subject>
<subj-group subj-group-type="heading">
<subject>Original scientific papers</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Cardiac rehabilitation decreases plasma pentraxin 3 in patients with cardiovascular diseases</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Fukuda</surname><given-names>Taira</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711422990">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kurano</surname><given-names>Miwa</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711422990">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Iida</surname><given-names>Haruko</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711422990">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Takano</surname><given-names>Haruhito</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711422990">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tanaka</surname><given-names>Tomofumi</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711422990">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Yamamoto</surname><given-names>Yumiko</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711422990">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ikeda</surname><given-names>Kenichi</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711422990">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nagasaki</surname><given-names>Mika</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711422990">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Monzen</surname><given-names>Koshiro</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711422990">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Uno</surname><given-names>Kansei</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711422990">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kato</surname><given-names>Masayoshi</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711422990">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Shiga</surname><given-names>Taro</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711422990">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Maemura</surname><given-names>Koji</given-names></name>
<xref ref-type="aff" rid="aff2-1741826711422990">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Masuda</surname><given-names>Nobuhito</given-names></name>
<xref ref-type="aff" rid="aff3-1741826711422990">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Yamashita</surname><given-names>Hiroshi</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711422990">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hirata</surname><given-names>Yasunobu</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711422990">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nagai</surname><given-names>Ryozo</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711422990">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Nakajima</surname><given-names>Toshiaki</given-names></name>
<xref ref-type="aff" rid="aff1-1741826711422990">1</xref>
<xref ref-type="corresp" rid="corresp1-1741826711422990"/>
</contrib>
</contrib-group>
<aff id="aff1-1741826711422990"><label>1</label>University of Tokyo, Tokyo, Japan.</aff>
<aff id="aff2-1741826711422990"><label>2</label>Nagasaki University, Nagasaki, Japan.</aff>
<aff id="aff3-1741826711422990"><label>3</label>Perseus Proteomics, Tokyo, Japan.</aff>
<author-notes>
<corresp id="corresp1-1741826711422990">Toshiaki Nakajima, Department of Ischemic Circulatory Physiology, University of Tokyo, Tokyo, Japan Email: <email>masamasa@pb4.so-net.ne.jp</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>12</month>
<year>2012</year>
</pub-date>
<volume>19</volume>
<issue>6</issue>
<fpage>1393</fpage>
<lpage>1400</lpage>
<history>
<date date-type="received"><day>6</day><month>4</month><year>2011</year></date>
<date date-type="accepted"><day>19</day><month>8</month><year>2011</year></date>
</history>
<permissions>
<copyright-statement>© The European Society of Cardiology 2011 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="society">European Society of Cardiology</copyright-holder>
</permissions>
<abstract>
<p><bold>Background:</bold> Inflammatory markers such as serum C-reactive protein (CRP), serum amyloid A (SAA), and plasma pentraxin 3 (PTX3), which belong to the pentraxin superfamily, increase due to various inflammatory diseases. Some studies demonstrated that serum CRP and SAA are predictors of cardiovascular diseases, and cardiac rehabilitation (CR) induces anti-inflammatory effects. In the present study, we investigated the effects of CR on pentraxins (serum CRP, SAA, and plasma PTX3) in patients with cardiovascular diseases.</p>
<p><bold>Methods:</bold> Fifty patients with cardiovascular diseases [61 ± 13 (mean ± SD) years old, male/female 44/6] participated. Each subject performed CR using aerobic bicycle exercise two or three times per week for 3–6 months. We measured resting serum high-sensitivity CRP (hsCRP), SAA, and plasma PTX3 before and 3 and 6 months after CR, and compared them with VO<sub>2peak</sub> determined using a standard increment cycle ergometer protocol, B-type natriuretic peptide (BNP), and other biochemical data such as HbA1c.</p>
<p><bold>Results:</bold> There was a significant positive correlation between hsCRP and SAA (<italic>r</italic> = 0.92, <italic>p</italic> &lt; 0.001), but no relations between these parameters and PTX3. Plasma PTX3 significantly decreased time dependently during CR (at baseline 3.2 ± 2.0 ng/ml, at 3 months 2.3 ± 0.8 ng/ml, at 6 months 2.1 ± 0.7 ng/ml; all <italic>p</italic> &lt; 0.05). Serum hsCRP tended to decrease, but not statistically significantly. At baseline, plasma PTX3 was negatively correlated with the percentage of the predicted values of VO<sub>2peak</sub> and positively correlated with BNP. CR significantly increased the percentage of the predicted values of VO<sub>2peak</sub> and decreased BNP.</p>
<p><bold>Conclusions:</bold> Plasma PTX3, an inflammatory marker, which was quite different from CRP and SAA, decreased during cardiac rehabilitation with an improvement of exercise capacity in patients with cardiovascular diseases.</p>
</abstract>
<kwd-group>
<kwd>Cardiac rehabilitation</kwd>
<kwd>high-sensitivity C-reactive protein</kwd>
<kwd>pentraxin 3</kwd>
<kwd>serum amyloid A</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1741826711422990" sec-type="intro"><title>Introduction</title>
<p>It has been established that exercise-based cardiac rehabilitation (CR) reduces all-cause mortality and cardiac mortality,<sup><xref ref-type="bibr" rid="bibr1-1741826711422990">1</xref>–<xref ref-type="bibr" rid="bibr5-1741826711422990">5</xref></sup> slows atherosclerotic process,<sup><xref ref-type="bibr" rid="bibr6-1741826711422990">6</xref></sup> and decreases rates of subsequent coronary events and rehospitalization.<sup><xref ref-type="bibr" rid="bibr3-1741826711422990">3</xref></sup> Thus, CR has been applied to patients who have experienced acute myocardial infarction or acute coronary syndrome, coronary artery bypass grafting surgery or cardiac valve surgery, and chronic heart failure.<sup><xref ref-type="bibr" rid="bibr7-1741826711422990">7</xref></sup> As this mechanisms, previous studies showed that CR not only had beneficial effects on coronary risk factors<sup><xref ref-type="bibr" rid="bibr8-1741826711422990">8</xref>,<xref ref-type="bibr" rid="bibr9-1741826711422990">9</xref></sup> but also decreased pro-inflammatory cytokines,<sup><xref ref-type="bibr" rid="bibr10-1741826711422990">10</xref>,<xref ref-type="bibr" rid="bibr11-1741826711422990">11</xref></sup> leading to improvement on exercise capacity.<sup><xref ref-type="bibr" rid="bibr12-1741826711422990">12</xref></sup></p>
<p>The long pentraxin 3 (PTX3) is a newly identified member of the pentraxin superfamily, which includes the short pentraxins C-reactive protein (CRP) and serum amyloid A (SAA). In contrast to short pentraxins mainly produced in the liver, PTX3 is synthesized locally at the inflammatory sites of various cell types including skeletal muscles, monocytes/macrophages, endothelial cells, and vascular smooth muscle cells<sup><xref ref-type="bibr" rid="bibr13-1741826711422990">13</xref>,<xref ref-type="bibr" rid="bibr14-1741826711422990">14</xref></sup> and is also involved in atherosclerotic lesions in response to inflammatory stimuli.<sup><xref ref-type="bibr" rid="bibr15-1741826711422990">15</xref></sup> Thus, PTX3 may be regarded as a more specific vascular inflammatory marker. Elevated plasma PTX3 levels have also been described in acute myocardial infarction,<sup><xref ref-type="bibr" rid="bibr16-1741826711422990">16</xref></sup> cardiac surgery,<sup><xref ref-type="bibr" rid="bibr17-1741826711422990">17</xref></sup> immediately after coronary stenting,<sup><xref ref-type="bibr" rid="bibr18-1741826711422990">18</xref></sup> and heart failure.<sup><xref ref-type="bibr" rid="bibr19-1741826711422990">19</xref></sup> Furthermore, PTX3 was implicated as a predictor of adverse clinical outcomes in patients with heart failure.<sup><xref ref-type="bibr" rid="bibr20-1741826711422990">20</xref></sup> Thus, it is very likely that plasma PTX3 may be a more useful and immediate inflammatory marker than other pentraxins in cardiovascular medicine.</p>
<p>Recently, it has been reported that CR using aerobic exercise had the favourable effects on serum high-sensitivity CRP (hsCRP).<sup><xref ref-type="bibr" rid="bibr6-1741826711422990">6</xref>,<xref ref-type="bibr" rid="bibr21-1741826711422990">21</xref></sup> However, the effects of CR on pentraxins including PTX3 remain unknown. The present study was performed to clarify how CR affects plasma PTX3 and compared PTX3 with serum CRP and SAA in patients with cardiovascular diseases receiving CR.</p>
</sec>
<sec id="sec2-1741826711422990" sec-type="methods"><title>Methods</title>
<sec id="sec3-1741826711422990" sec-type="subjects"><title>Subjects</title>
<p>Fifty patients with cardiovascular diseases who referred to CR (male/female 44/6; age 61 ± 13 years old; height 166 ± 9 cm; weight 68 ± 15 kg; body mass index 24.6 ± 3.6 kg/m<sup>2</sup>) participated in the present study. The underlying cardiovascular diseases included ischaemic heart diseases in 42 patients, dilated cardiomyopathy in seven patients, and arteriosclerosis obliterans in one patient. According to the New York Heart Association (NYHA) classification of functional capacity, four patients were in class I, 35 patients were in class II, and 11 patients were in class III (<xref ref-type="table" rid="table1-1741826711422990">Table 1</xref>). Left anterior descending artery, left circumflex artery, and right coronary artery lesions were identified in 39 (93%), 19 (45%), and 24 (57%) of coronary patients, suggesting that many patients with ischaemic heart diseases had multiple coronary lesions. Myocardial infarction was identified in 25 (60%), and percutaneous coronary intervention, which used drug eluting stents in 34 (81%), was performed for not less than 75% stenosis in 38 (90%). Only four patients have had coronary artery bypass grafting surgery especially in those with left anterior descending artery involvement. On the other hand, seven patients with dilated cardiomyopathy were not ischaemic. Hypertension, diabetes mellitus, and past smoking were identified in 35 (70%), 19 (38%), and 32 (64%) of patients, respectively. More than half patients used statins, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and β blockers, and almost a quarter of the patients used diuretics. The treatment regimen had not been changed during the 6-month follow-up period. Thus, no treatment interfered with inflammatory status. The B-type natriuretic peptide (BNP) level before CR was 155.5 ± 206.7 pg/ml, suggesting that the cardiovascular diseases were stable. The present study was approved by the Ethics Committee of the University of Tokyo. All subjects were informed of the methods, procedures, and risks, and signed an informed consent document before participation.
<table-wrap id="table1-1741826711422990" position="float"><label>Table 1.</label><caption><p>Clinical characteristics of 50 patients with cardiovascular diseases</p></caption>
<graphic alternate-form-of="table1-1741826711422990" xlink:href="10.1177_1741826711422990-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Characteristic</th>
<th>All patients (<italic>n</italic> = 50)</th></tr></thead>
<tbody align="left">
<tr>
<td>Age (years)</td>
<td>61 ± 13</td></tr>
<tr>
<td>Male/female</td>
<td>44/6</td></tr>
<tr>
<td>LVEF (%)</td>
<td>53 ± 16</td></tr>
<tr>
<td>Height (cm)</td>
<td>166 ± 9</td></tr>
<tr>
<td>Weight (kg)</td>
<td>68 ± 15</td></tr>
<tr>
<td>BMI (kg/m<sup>2</sup>)</td>
<td>24.6 ± 3.6</td></tr>
<tr>
<td>CABG</td>
<td>4 (10)</td></tr>
<tr>
<td>LAD</td>
<td>39 (93)</td></tr>
<tr>
<td>LCX</td>
<td>19 (45)</td></tr>
<tr>
<td>RCA</td>
<td>24 (57)</td></tr>
<tr>
<td>NYHA I/II/III</td>
<td>4/35/11</td></tr>
<tr>
<td>Smoking</td>
<td>32 (64)</td></tr>
<tr>
<td>Diabetes mellitus</td>
<td>19 (38)</td></tr>
<tr>
<td>Hypertension</td>
<td>35 (70)</td></tr>
<tr>
<td>Statins</td>
<td>38 (76)</td></tr>
<tr>
<td>ACEIs</td>
<td>32 (64)</td></tr>
<tr>
<td>ARBs</td>
<td>15 (30)</td></tr>
<tr>
<td>β blockers</td>
<td>36 (72)</td></tr>
<tr>
<td>Diuretics</td>
<td>14 (28)</td></tr>
<tr>
<td>LDL (mg/dl)</td>
<td>96.2 ± 22.0 (<italic>n</italic> = 48)</td></tr>
<tr>
<td>HDL (mg/dl)</td>
<td>50.6 ± 15.5 (<italic>n</italic> = 48)</td></tr>
<tr>
<td>TG (mg/dl)</td>
<td>125.8 ± 56.7 (<italic>n</italic> = 49)</td></tr>
<tr>
<td>HbA1c (%)</td>
<td>5.9 ± 0.8 (<italic>n</italic> = 42)</td></tr>
<tr>
<td>BNP (pg/ml)</td>
<td>155.5 ± 206.7 (<italic>n</italic> = 45)</td></tr>
<tr>
<td>VO<sub>2peak</sub> (ml/kg/min)</td>
<td>15.2 ± 3.2 (<italic>n</italic> = 48)</td></tr>
<tr>
<td>%VO<sub>2peak</sub> (%)</td>
<td>61 ± 13 (<italic>n</italic> = 48)</td></tr>
<tr>
<td>SBP (mmHg)</td>
<td>112 ± 22 (<italic>n</italic> = 49)</td></tr>
<tr>
<td>DBP (mmHg)</td>
<td>68 ± 12 (<italic>n</italic> = 49)</td></tr>
<tr>
<td>HR (bpm)</td>
<td>71 ± 11 (<italic>n</italic> = 49)</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1741826711422990"><p>Values are mean ± standard deviation or <italic>n</italic> (%). ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BNP, B-type natriuretic peptide; CABG, coronary artery bypass grafting; DBP, diastolic blood pressure; HbA1c, haemoglobin A1c; HDL, high-density lipoprotein cholesterol; HR, heart rate; LAD, left anterior descending artery; LCX, left circumflex artery; LDL, low-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; RCA, right coronary artery; SBP, systolic blood pressure; TG, triglyceride; %VO<sub>2peak</sub>, percentage of the predicted values of VO<sub>2peak</sub>.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec4-1741826711422990"><title>Rehabilitation protocol and measurement of VO<sub>2</sub></title>
<p>Before CR, a symptom-limited exercise test on an electromagnetically braked upright cycle ergometer (Corival, Load, Holland) at least 2 h after a meal were performed to determine peak VO<sub>2</sub> (VO<sub>2peak</sub>) and anaerobic threshold. After a 4-min rest on the cycle ergometer, exercise was started at 20 W for a 4-min warm up and work rate was then increased in 1-W increments every 6 s. Blood pressure was measured by an automatic indirect cuff manometer (FB-300; Fukuda Denshi, Tokyo, Japan) every minute. Subjects stopped exercising because of leg fatigue or dyspnoea. Expired gases were measured continuously in all subjects on a breath-by-breath basis using an expired gas analyser (AE-300S; Minato Medical Science, Osaka, Japan). Ventilatory parameters, including VO<sub>2</sub>, carbon dioxide output (VCO<sub>2</sub>) and minute ventilation were calculated. ECG was monitored throughout the test to detect possible ECG signal abnormalities (ML-9000; Fukuda Denshi, Tokyo, Japan). Then, each subject visited the laboratory to receive CR using aerobic bicycle exercise of 70–75% anaerobic threshold levels two or three times per week during 3–6 months. At 3 and 6 months, a symptom-limited exercise test was again performed to determine VO<sub>2peak</sub> and anaerobic threshold. All patients quit the test because of dyspnoea or fatigue, and in all patients respiratory exchange ratio of more than 1.10 were reached. VO<sub>2peak</sub> was reported as the mean value during the last minute of exercise. A mean value of VO<sub>2peak</sub> was shown in <xref ref-type="table" rid="table1-1741826711422990">Table 1</xref> and the percentage of the predicted values of VO<sub>2peak</sub> (%VO<sub>2peak</sub>) of a patient with arteriosclerosis obliterans was 70%.</p>
</sec>
<sec id="sec5-1741826711422990"><title>Blood sampling and analysis</title>
<p>At baseline (pre-CR) and 3 and 6 months after CR, blood samples were obtained to measure resting levels of serum hsCRP, SAA, plasma PTX3, BNP, lipid profiles, HbA1c, and other biochemical markers. All samples were kept in ice-cold water and centrifuged (1500 g) for 10 minutes and the plasma was stored at −20°C until the assays were performed. HsCRP and SAA were measured at SRL (Tokyo, Japan) in 500 µl serum samples, using a method of latex turbidimetric immunoassay (LTIA). The limits of detection for hsCRP and SAA were 50 ng/ml and 2.5 µg/ml, respectively. Plasma PTX3 was measured at Perseus Proteomics (Tokyo, Japan), using a sandwich ELISA technique as previously reported.<sup><xref ref-type="bibr" rid="bibr22-1741826711422990">22</xref></sup> The limit of detection of the PTX3 assay was 0.1 ng/ml.</p>
</sec>
<sec id="sec6-1741826711422990"><title>Data analysis</title>
<p>All values were expressed as the mean ± standard deviation. Significance between two groups was determined by unpaired Student's t-test for continuous variables and by χ<sup>2</sup> test for discrete variables. Student's pared t-test was used to compare two sets of data from the same subjects. Spearman's rank correlation coefficient (<italic>r</italic>) was used to examine the relationship between two parameters. Differences were considered significant if <italic>p</italic> values were less than 0.05.</p>
</sec>
</sec>
<sec id="sec7-1741826711422990" sec-type="results"><title>Results</title>
<p>Firstly, we investigated the relationships among hsCRP, SAA, and PTX3 in patients with cardiovascular diseases at rest. <xref ref-type="fig" rid="fig1-1741826711422990">Figure 1</xref> shows that there were no relations between PTX3 and hsCRP or SAA, whereas there was a significant positive correlation between serum hsCRP and SAA (<italic>r</italic> = 0.92, <italic>p</italic> &lt; 0.001).
<fig id="fig1-1741826711422990" position="float"><label>Figure 1.</label><caption><p>Relationships between plasma pentraxin 3 (PTX3), and serum high-sensitivity C-reactive protein (hsCRP) and serum amyloid A (SAA) before and 3–6 months after cardiac rehabilitation in patients with cardiovascular diseases.</p></caption><graphic xlink:href="10.1177_1741826711422990-fig1.tif"/></fig></p>
<p>Systolic blood pressure significantly decreased after 3 months (pre-CR vs. 3 months, 112 ± 22 vs. 105 ± 16 mmHg; <italic>p</italic> &lt; 0.05), and heart rate and diastolic blood pressure tended to decrease after 3 months (heart rate: pre-CR vs. 3 months, 71 ± 11 vs. 70 ± 9 mmHg, <italic>p</italic> = NS; diastolic blood pressure: pre-CR vs. 3 months, 68 ± 12 vs. 67 ± 9 mmHg, <italic>p</italic> = NS). However, there were no correlations between changes in heart rate, blood pressure, and PTX3. <xref ref-type="table" rid="table2-1741826711422990">Table 2</xref> and <xref ref-type="fig" rid="fig2-1741826711422990">Figure 2</xref> show relationships between serum hsCRP, plasma PTX3, and other factors before CR. Plasma PTX3 was negatively correlated with %VO<sub>2peak</sub> (<italic>p</italic> &lt; 0.01) and positively correlated with plasma BNP (<italic>p</italic> &lt; 0.05) with low correlation coefficients (0.36 and 0.26 respectively), whereas serum hsCRP was not related to these factors (<xref ref-type="fig" rid="fig2-1741826711422990">Figure 2</xref>). Plasma PTX3 tended to be positively correlated with HbA1c (<italic>p</italic> = 0.094).
<fig id="fig2-1741826711422990" position="float"><label>Figure 2.</label><caption><p>Relationships between plasma pentraxin 3 (PTX3), and the percentage of the predicted values of VO<sub>2peak</sub> and plasma B-type natriuretic peptide (BNP) before cardiac rehabilitation in patients with cardiovascular diseases.</p></caption><graphic xlink:href="10.1177_1741826711422990-fig2.tif"/></fig>
<table-wrap id="table2-1741826711422990" position="float"><label>Table 2.</label><caption><p>Relationships between hsCRP, PTX3, and other factors before cardiac rehabilitation in patients with cardiovascular diseases</p></caption>
<graphic alternate-form-of="table2-1741826711422990" xlink:href="10.1177_1741826711422990-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th/>
<th>PTX3</th>
<th/>
<th>hsCRP</th>
<th/></tr>
<tr><th/>
<th>Coefficient</th>
<th><italic>p</italic>-value</th>
<th>Coefficient</th>
<th><italic>p</italic>-value</th></tr></thead>
<tbody align="left">
<tr>
<td>BMI</td>
<td>0.0018</td>
<td>0.49</td>
<td>43.14</td>
<td>0.25</td></tr>
<tr>
<td>VO<sub>2peak</sub> (ml/kg/min)</td>
<td>−0.10</td>
<td>0.065</td>
<td>−101.11</td>
<td>0.10</td></tr>
<tr>
<td>%VO<sub>2peak</sub></td>
<td>−0.014</td>
<td>0.008<sup><xref ref-type="table-fn" rid="table-fn2-1741826711422990">a</xref></sup></td>
<td>−17.75</td>
<td>0.18</td></tr>
<tr>
<td>BNP</td>
<td>0.0011</td>
<td>0.045<sup><xref ref-type="table-fn" rid="table-fn3-1741826711422990">b</xref></sup></td>
<td>−0.39</td>
<td>0.39</td></tr>
<tr>
<td>LDL</td>
<td>0.0058</td>
<td>0.33</td>
<td>11.84</td>
<td>0.10</td></tr>
<tr>
<td>HDL</td>
<td>−0.0006</td>
<td>0.48</td>
<td>−4.86</td>
<td>0.35</td></tr>
<tr>
<td>TG</td>
<td>−0.0021</td>
<td>0.34</td>
<td>1.65</td>
<td>0.34</td></tr>
<tr>
<td>HbA1c</td>
<td>0.41</td>
<td>0.094</td>
<td>−347.18</td>
<td>0.13</td></tr>
<tr>
<td>hsCRP</td>
<td>−0.0001</td>
<td>0.29</td>
<td>–</td>
<td>–</td></tr>
<tr>
<td>PTX3</td>
<td>–</td>
<td>–</td>
<td>−62.83</td>
<td>0.29</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1741826711422990"><label>a</label><p><italic>p </italic>&lt; 0.01</p></fn>
<fn id="table-fn3-1741826711422990"><label>b</label><p><italic>p</italic> &lt; 0.05. BMI, body mass index; BNP, B-type natriuretic peptide; HbA1c, haemoglobin A1c; HDL, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein cholesterol; PTX3, pentraxin 3; TG, triglyceride; %VO<sub>2peak</sub>, percentage of the predicted values of VO<sub>2peak</sub>.</p></fn></table-wrap-foot>
</table-wrap></p>
<p><xref ref-type="fig" rid="fig3-1741826711422990">Figure 3</xref> shows that plasma PTX3 significantly decreased time dependently (at baseline 3.2 ± 2.0 ng/ml, at 3 months 2.3 ± 0.8 ng/ml, at 6 months; 2.1 ± 0.7 ng/ml; all <italic>p</italic> &lt; 0.01). On the other hand, serum hsCRP (<xref ref-type="fig" rid="fig3-1741826711422990">Figure 3</xref>) and SAA (data not shown) tended to decrease time dependently, but the decrease was not statistically significant.
<fig id="fig3-1741826711422990" position="float"><label>Figure 3.</label><caption><p>Time-dependent effects of cardiac rehabilitation on plasma pentraxin 3 (PTX3) and serum high-sensitive C-reactive protein (hsCRP).</p></caption><graphic xlink:href="10.1177_1741826711422990-fig3.tif"/></fig></p>
<p><xref ref-type="fig" rid="fig4-1741826711422990">Figure 4</xref> shows that VO<sub>2peak</sub> and %VO<sub>2peak</sub> significantly increased after 3–6 months (VO<sub>2peak</sub>, 3 months + 12.7%, 6 months + 17.8%; both <italic>p</italic> &lt; 0.001) and BNP significantly decreased.
<fig id="fig4-1741826711422990" position="float"><label>Figure 4.</label><caption><p>Time-dependent effects of cardiac rehabilitation on the percentage of the predicted values of VO<sub>2peak</sub> and plasma B-type natriuretic peptide (BNP).</p></caption><graphic xlink:href="10.1177_1741826711422990-fig4.tif"/></fig></p>
</sec>
<sec id="sec8-1741826711422990" sec-type="discussion"><title>Discussion</title>
<p>The major findings of the present study are as follows. (1) There was a significant positive correlation between serum hsCRP and SAA, but no relations between these parameters and plasma PTX3 in patients with cardiovascular diseases receiving CR. (2) Before CR, plasma PTX3 was negatively correlated with %VO<sub>2peak</sub> and positively correlated with plasma BNP. (3) CR decreased plasma PTX3 time dependently, whereas it did not significantly decrease serum hsCRP and SAA with an improvement of exercise capacity in patients with cardiovascular diseases. These results suggest that plasma PTX3, an inflammatory marker quite different from CRP and SAA, decreases during cardiac rehabilitation with an improvement of exercise capacity in patients with cardiovascular diseases.</p>
<p>The results of the present study have several important implications. First, we demonstrated that in patients with established cardiovascular diseases, there was a significant positive correlation between serum hsCRP and SAA. SAA, a family of apolipoproteins associated with high-density lipoproteins in plasma, is produced predominantly by the liver in response to inflammation but also by endothelial cells, smooth muscle cells, and macrophages at atherosclerotic lesions,<sup><xref ref-type="bibr" rid="bibr23-1741826711422990">23</xref>,<xref ref-type="bibr" rid="bibr24-1741826711422990">24</xref></sup> which was almost similar to CRP. Previous data on this issue have been derived from studies using subjects without cardiovascular diseases.<sup><xref ref-type="bibr" rid="bibr25-1741826711422990">25</xref>,<xref ref-type="bibr" rid="bibr26-1741826711422990">26</xref></sup> Thus, the present study suggested that in patients with known cardiovascular diseases, serum hsCRP and SAA were also well related. Also, in the present study, no correlations were found between these parameters and plasma PTX3, suggesting that these short pentraxins (hsCRP and SAA) and PTX3 were independent markers of inflammation, as previously described in subjects without cardiovascular disease.<sup><xref ref-type="bibr" rid="bibr22-1741826711422990">22</xref></sup> Although PTX3 is a member of the pentraxin protein family, it differs from CRP in gene organization, cellular source, and ligands recognized.<sup><xref ref-type="bibr" rid="bibr15-1741826711422990">15</xref>,<xref ref-type="bibr" rid="bibr27-1741826711422990">27</xref></sup> Also, CRP and SAA are mainly produced by hepatocytes mainly in response to the proinflammatory cytokines interleukin 6 and interleukin 1, whereas PTX3 is produced by the major cell types involved in atherosclerotic lesions in response to inflammatory stimuli such as tumour necrosis factor α, interleukin 1, and oxidized low-density lipoprotein cholesterol.<sup><xref ref-type="bibr" rid="bibr15-1741826711422990">15</xref></sup> Therefore, it is likely that plasma PTX3 may be regarded as such a more specific vascular inflammatory marker, and CR using aerobic exercise decreased only plasma PTX3 in the present study.</p>
<p>Second, the present study showed that before CR, plasma PTX3 was negatively correlated with %VO<sub>2peak</sub> and positively correlated with plasma BNP. Previous studies showed that the number of patients with heart failure was greater in the cardiovascular patients with elevated PTX3 values, suggesting a relationship between PTX3 levels and heart failure.<sup><xref ref-type="bibr" rid="bibr16-1741826711422990">16</xref>,<xref ref-type="bibr" rid="bibr28-1741826711422990">28</xref></sup> Also, Suzuki et al.<sup><xref ref-type="bibr" rid="bibr20-1741826711422990">20</xref></sup> reported that plasma PTX3 was increased in patients with heart failure and increased with advancing NYHA functional class. The present study showed that the PTX3 level was negatively correlated with exercise capacity. However, plasma PTX3 was not different in different NYHA functional classes (data not shown), probably because of relatively small numbers of patients.</p>
<p>Third, in the present study, CR decreased plasma PTX3 time dependently. On the other hand, it tended to decrease serum hsCRP, but not statistically significantly. Daily regular exercise is known to induce anti-inflammatory effects and protect against the risk of cardiovascular diseases associated with chronic low-grade systemic inflammation such as atherosclerosis,<sup><xref ref-type="bibr" rid="bibr29-1741826711422990">29</xref></sup> resulting in a decrease in serum CRP.<sup><xref ref-type="bibr" rid="bibr30-1741826711422990">30</xref>,<xref ref-type="bibr" rid="bibr31-1741826711422990">31</xref></sup> A few previous studies have prospectively examined the effect of exercise training on both serum CRP and SAA.<sup><xref ref-type="bibr" rid="bibr32-1741826711422990">32</xref>,<xref ref-type="bibr" rid="bibr33-1741826711422990">33</xref></sup> Patients with intermittent claudication demonstrated that CRP and SAA levels were significantly reduced after 3–6 months of supervised exercise compared with controls.<sup><xref ref-type="bibr" rid="bibr32-1741826711422990">32</xref></sup> Also, significant reduction in both serum CRP and SAA was observed in subjects with coronary heart disease who performed CR more than 2 times per week.<sup><xref ref-type="bibr" rid="bibr33-1741826711422990">33</xref></sup> However, as long as we know, no previous study has prospectively examined the effect of CR on plasma PTX3. In the present study, CR did not significantly decrease either serum CRP or SAA, probably due to small number of subjects. Nevertheless, CR decreased plasma PTX3 time dependently. Mechanisms of the PTX3 decrease during CR may be modulations of angiogenesis, thrombogenesis, and atherosclerotic plaque. In addition, heart failure is a systemic disorder that affects not only cardiovascular and musculoskeletal systems but also inflammation and immune systems.<sup><xref ref-type="bibr" rid="bibr34-1741826711422990">34</xref>–<xref ref-type="bibr" rid="bibr38-1741826711422990">38</xref></sup> Thus, plasma PTX3 may be a more sensitive marker of beneficial effect of CR compared with both serum hsCRP and SAA in patients with heart failure as well as cardiovascular diseases. However, further studies are needed to clarify this possibility.</p>
<p>There may be several possible explanations why plasma PTX3 seems to be a more robust vascular inflammatory marker than serum hsCRP in patients with cardiovascular diseases. In our previous study, when the daily variation of plasma PTX3 and serum CRP level was measured from healthy subjects on different days, plasma PTX3 was relatively stable compared with serum hsCRP,<sup><xref ref-type="bibr" rid="bibr22-1741826711422990">22</xref></sup> which was consistent with the present study. However, there are some limitations in the present study. First, there was the heterogeneity of subjects such as ischaemic heart disease, dilated cardiomyopathy, and arteriosclerosis obliterans. Lastly, the present study was the relatively short cohort. Therefore, the results of the present study may require more investigations.</p>
</sec>
<sec id="sec9-1741826711422990" sec-type="conclusions"><title>Conclusions</title>
<p>In patients with cardiovascular diseases receiving CR, plasma PTX3, an inflammatory marker quite different from CRP and SAA, was negatively correlated with exercise capacity and positively correlated with BNP. Also, PTX3 during CR significantly decreased with an improvement of exercise capacity.</p>
</sec>
</body>
<back>
<sec id="sec10-1741826711422990"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="sec11-1741826711422990"><title>Conflict of interests</title>
<p>None.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-1741826711422990"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>RS</given-names></name><name><surname>Brown</surname><given-names>A</given-names></name><name><surname>Ebrahim</surname><given-names>S</given-names></name><name><surname>Jolliffe</surname><given-names>J</given-names></name><name><surname>Noorani</surname><given-names>H</given-names></name><name><surname>Rees</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials</article-title>. <source>Am J Med</source> <year>2004</year>; <volume>116</volume>(<issue>10</issue>): <fpage>682</fpage>–<lpage>692</lpage>.</citation></ref>
<ref id="bibr2-1741826711422990"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hammill</surname><given-names>BG</given-names></name><name><surname>Curtis</surname><given-names>LH</given-names></name><name><surname>Schulman</surname><given-names>KA</given-names></name><name><surname>Whellan</surname><given-names>DJ</given-names></name></person-group>. <article-title>Relationship between cardiac rehabilitation and long-term risks of death and myocardial infarction among elderly medicare beneficiaries</article-title>. <source>Circulation</source> <year>2010</year>; <volume>121</volume>(<issue>1</issue>): <fpage>63</fpage>–<lpage>70</lpage>.</citation></ref>
<ref id="bibr3-1741826711422990"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>AM</given-names></name><name><surname>Hartling</surname><given-names>L</given-names></name><name><surname>Vandermeer</surname><given-names>B</given-names></name><name><surname>McAlister</surname><given-names>FA</given-names></name></person-group>. <article-title>Meta-analysis: secondary prevention programs for patients with coronary artery disease</article-title>. <source>Ann Intern Med</source> <year>2005</year>; <volume>143</volume>(<issue>9</issue>): <fpage>659</fpage>–<lpage>672</lpage>.</citation></ref>
<ref id="bibr4-1741826711422990"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piepoli</surname><given-names>MF</given-names></name><name><surname>Corra</surname><given-names>U</given-names></name><name><surname>Benzer</surname><given-names>W</given-names></name><name><surname>Bjarnason-Wehrens</surname><given-names>B</given-names></name><name><surname>Dendale</surname><given-names>P</given-names></name><name><surname>Gaita</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the cardiac rehabilitation section of the European association of cardiovascular prevention and rehabilitation</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2010</year>; <volume>17</volume>(<issue>1</issue>): <fpage>1</fpage>–<lpage>17</lpage>.</citation></ref>
<ref id="bibr5-1741826711422990"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giannuzzi</surname><given-names>P</given-names></name><name><surname>Mezzani</surname><given-names>A</given-names></name><name><surname>Saner</surname><given-names>H</given-names></name><name><surname>Bjornstad</surname><given-names>H</given-names></name><name><surname>Fioretti</surname><given-names>P</given-names></name><name><surname>Mendes</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Physical activity for primary and secondary prevention. Position paper of the working group on cardiac rehabilitation and exercise physiology of the European society of cardiology</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2003</year>; <volume>10</volume>(<issue>5</issue>): <fpage>319</fpage>–<lpage>327</lpage>.</citation></ref>
<ref id="bibr6-1741826711422990"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dod</surname><given-names>HS</given-names></name><name><surname>Bhardwaj</surname><given-names>R</given-names></name><name><surname>Sajja</surname><given-names>V</given-names></name><name><surname>Weidner</surname><given-names>G</given-names></name><name><surname>Hobbs</surname><given-names>GR</given-names></name><name><surname>Konat</surname><given-names>GW</given-names></name><etal/></person-group>. <article-title>Effect of intensive lifestyle changes on endothelial function and on inflammatory markers of atherosclerosis</article-title>. <source>Am J Cardiol</source> <year>2010</year>; <volume>105</volume>(<issue>3</issue>): <fpage>362</fpage>–<lpage>367</lpage>.</citation></ref>
<ref id="bibr7-1741826711422990"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>MA</given-names></name><name><surname>Ades</surname><given-names>PA</given-names></name><name><surname>Hamm</surname><given-names>LF</given-names></name><name><surname>Keteyian</surname><given-names>SJ</given-names></name><name><surname>LaFontaine</surname><given-names>TP</given-names></name><name><surname>Roitman</surname><given-names>JL</given-names></name><etal/></person-group>. <article-title>Clinical evidence for a health benefit from cardiac rehabilitation: an update</article-title>. <source>Am Heart J</source> <year>2006</year>; <volume>152</volume>(<issue>5</issue>): <fpage>835</fpage>–<lpage>841</lpage>.</citation></ref>
<ref id="bibr8-1741826711422990"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lavie</surname><given-names>CJ</given-names></name><name><surname>Milani</surname><given-names>RV</given-names></name><name><surname>Littman</surname><given-names>AB</given-names></name></person-group>. <article-title>Benefits of cardiac rehabilitation and exercise training in secondary coronary prevention in the elderly</article-title>. <source>J Am Coll Cardiol</source> <year>1993</year>; <volume>22</volume>(<issue>3</issue>): <fpage>678</fpage>–<lpage>683</lpage>.</citation></ref>
<ref id="bibr9-1741826711422990"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lavie</surname><given-names>CJ</given-names></name><name><surname>Milani</surname><given-names>RV</given-names></name></person-group>. <article-title>Effects of cardiac rehabilitation, exercise training, and weight reduction on exercise capacity, coronary risk factors, behavioral characteristics, and quality of life in obese coronary patients</article-title>. <source>Am J Cardiol</source> <year>1997</year>; <volume>79</volume>(<issue>4</issue>): <fpage>397</fpage>–<lpage>401</lpage>.</citation></ref>
<ref id="bibr10-1741826711422990"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adamopoulos</surname><given-names>S</given-names></name><name><surname>Parissis</surname><given-names>J</given-names></name><name><surname>Karatzas</surname><given-names>D</given-names></name><name><surname>Kroupis</surname><given-names>C</given-names></name><name><surname>Georgiadis</surname><given-names>M</given-names></name><name><surname>Karavolias</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure</article-title>. <source>J Am Coll Cardiol</source> <year>2002</year>; <volume>39</volume>(<issue>4</issue>): <fpage>653</fpage>–<lpage>663</lpage>.</citation></ref>
<ref id="bibr11-1741826711422990"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gielen</surname><given-names>S</given-names></name><name><surname>Adams</surname><given-names>V</given-names></name><name><surname>Mobius-Winkler</surname><given-names>S</given-names></name><name><surname>Linke</surname><given-names>A</given-names></name><name><surname>Erbs</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Anti-inflammatory effects of exercise training in the skeletal muscle of patients with chronic heart failure</article-title>. <source>J Am Coll Cardiol</source> <year>2003</year>; <volume>42</volume>(<issue>5</issue>): <fpage>861</fpage>–<lpage>868</lpage>.</citation></ref>
<ref id="bibr12-1741826711422990"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Valkeinen</surname><given-names>H</given-names></name><name><surname>Aaltonen</surname><given-names>S</given-names></name><name><surname>Kujala</surname><given-names>UM</given-names></name></person-group>. <article-title>Effects of exercise training on oxygen uptake in coronary heart disease: a systematic review and meta-analysis</article-title>. <source>Scand J Med Sci Sports</source> <year>2010</year>; <volume>20</volume>(<issue>4</issue>): <fpage>545</fpage>–<lpage>555</lpage>.</citation></ref>
<ref id="bibr13-1741826711422990"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Garlanda</surname><given-names>C</given-names></name><name><surname>Doni</surname><given-names>A</given-names></name><name><surname>Bottazzi</surname><given-names>B</given-names></name></person-group>. <article-title>Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3</article-title>. <source>J Clin Immunol</source> <year>2008</year>; <volume>28</volume>(<issue>1</issue>): <fpage>1</fpage>–<lpage>13</lpage>.</citation></ref>
<ref id="bibr14-1741826711422990"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Presta</surname><given-names>M</given-names></name><name><surname>Camozzi</surname><given-names>M</given-names></name><name><surname>Salvatori</surname><given-names>G</given-names></name><name><surname>Rusnati</surname><given-names>M</given-names></name></person-group>. <article-title>Role of the soluble pattern recognition receptor PTX3 in vascular biology</article-title>. <source>J Cell Mol Med</source> <year>2007</year>; <volume>11</volume>(<issue>4</issue>): <fpage>723</fpage>–<lpage>738</lpage>.</citation></ref>
<ref id="bibr15-1741826711422990"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garlanda</surname><given-names>C</given-names></name><name><surname>Bottazzi</surname><given-names>B</given-names></name><name><surname>Bastone</surname><given-names>A</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group>. <article-title>Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility</article-title>. <source>Annu Rev Immunol</source> <year>2005</year>; <volume>23</volume>(<issue>1</issue>): <fpage>337</fpage>–<lpage>366</lpage>.</citation></ref>
<ref id="bibr16-1741826711422990"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Latini</surname><given-names>R</given-names></name><name><surname>Maggioni</surname><given-names>AP</given-names></name><name><surname>Peri</surname><given-names>G</given-names></name><name><surname>Gonzini</surname><given-names>L</given-names></name><name><surname>Lucci</surname><given-names>D</given-names></name><name><surname>Mocarelli</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction</article-title>. <source>Circulation</source> <year>2004</year>; <volume>110</volume>(<issue>16</issue>): <fpage>2349</fpage>–<lpage>2354</lpage>.</citation></ref>
<ref id="bibr17-1741826711422990"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kunes</surname><given-names>P</given-names></name><name><surname>Lonsky</surname><given-names>V</given-names></name><name><surname>Mandak</surname><given-names>J</given-names></name><name><surname>Kolackova</surname><given-names>M</given-names></name><name><surname>Andrys</surname><given-names>C</given-names></name><name><surname>Kudlova</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>The long pentraxin 3 in cardiac surgery: distinct responses in ‘on-pump’ and ‘off-pump’ patients</article-title>. <source>Scand Cardiovasc J</source> <year>2007</year>; <volume>41</volume>(<issue>3</issue>): <fpage>171</fpage>–<lpage>179</lpage>.</citation></ref>
<ref id="bibr18-1741826711422990"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kotooka</surname><given-names>N</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Fujimatsu</surname><given-names>D</given-names></name><name><surname>Morooka</surname><given-names>T</given-names></name><name><surname>Hashimoto</surname><given-names>S</given-names></name><name><surname>Hikichi</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening</article-title>. <source>Atherosclerosis</source> <year>2008</year>; <volume>197</volume>(<issue>1</issue>): <fpage>368</fpage>–<lpage>374</lpage>.</citation></ref>
<ref id="bibr19-1741826711422990"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsubara</surname><given-names>J</given-names></name><name><surname>Sugiyama</surname><given-names>S</given-names></name><name><surname>Nozaki</surname><given-names>T</given-names></name><name><surname>Sugamura</surname><given-names>K</given-names></name><name><surname>Konishi</surname><given-names>M</given-names></name><name><surname>Ohba</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction</article-title>. <source>J Am Coll Cardiol</source> <year>2011</year>; <volume>57</volume>(<issue>7</issue>): <fpage>861</fpage>–<lpage>869</lpage>.</citation></ref>
<ref id="bibr20-1741826711422990"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>S</given-names></name><name><surname>Takeishi</surname><given-names>Y</given-names></name><name><surname>Niizeki</surname><given-names>T</given-names></name><name><surname>Koyama</surname><given-names>Y</given-names></name><name><surname>Kitahara</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure</article-title>. <source>Am Heart J</source> <year>2008</year>; <volume>155</volume>(<issue>1</issue>): <fpage>75</fpage>–<lpage>81</lpage>.</citation></ref>
<ref id="bibr21-1741826711422990"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Milani</surname><given-names>RV</given-names></name><name><surname>Lavie</surname><given-names>CJ</given-names></name><name><surname>Mehra</surname><given-names>MR</given-names></name></person-group>. <article-title>Reduction in C-reactive protein through cardiac rehabilitation and exercise training</article-title>. <source>J Am Coll Cardiol</source> <year>2004</year>; <volume>43</volume>(<issue>6</issue>): <fpage>1056</fpage>–<lpage>1061</lpage>.</citation></ref>
<ref id="bibr22-1741826711422990"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakajima</surname><given-names>T</given-names></name><name><surname>Kurano</surname><given-names>M</given-names></name><name><surname>Hasegawa</surname><given-names>T</given-names></name><name><surname>Takano</surname><given-names>H</given-names></name><name><surname>Iida</surname><given-names>H</given-names></name><name><surname>Yasuda</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Pentraxin3 and high-sensitive C-reactive protein are independent inflammatory markers released during high-intensity exercise</article-title>. <source>Eur J Appl Physiol</source> <year>2010</year>; <volume>110</volume>(<issue>5</issue>): <fpage>905</fpage>–<lpage>913</lpage>.</citation></ref>
<ref id="bibr23-1741826711422990"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brissette</surname><given-names>L</given-names></name><name><surname>Young</surname><given-names>I</given-names></name><name><surname>Narindrasorasak</surname><given-names>S</given-names></name><name><surname>Kisilevsky</surname><given-names>R</given-names></name><name><surname>Deeley</surname><given-names>R</given-names></name></person-group>. <article-title>Differential induction of the serum amyloid A gene family in response to an inflammatory agent and to amyloid-enhancing factor</article-title>. <source>J Biol Chem</source> <year>1989</year>; <volume>264</volume>(<issue>32</issue>): <fpage>19327</fpage>–<lpage>19332</lpage>.</citation></ref>
<ref id="bibr24-1741826711422990"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meek</surname><given-names>RL</given-names></name><name><surname>Urieli-Shoval</surname><given-names>S</given-names></name><name><surname>Benditt</surname><given-names>EP</given-names></name></person-group>. <article-title>Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>1994</year>; <volume>91</volume>(<issue>8</issue>): <fpage>3186</fpage>–<lpage>3190</lpage>.</citation></ref>
<ref id="bibr25-1741826711422990"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herder</surname><given-names>C</given-names></name><name><surname>Peltonen</surname><given-names>M</given-names></name><name><surname>Koenig</surname><given-names>W</given-names></name><name><surname>Kraft</surname><given-names>I</given-names></name><name><surname>Muller-Scholze</surname><given-names>S</given-names></name><name><surname>Martin</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes</article-title>. <source>Diabetes</source> <year>2006</year>; <volume>55</volume>(<issue>8</issue>): <fpage>2340</fpage>–<lpage>2346</lpage>.</citation></ref>
<ref id="bibr26-1741826711422990"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Danesh</surname><given-names>J</given-names></name><name><surname>Muir</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>YK</given-names></name><name><surname>Ward</surname><given-names>M</given-names></name><name><surname>Gallimore</surname><given-names>JR</given-names></name><name><surname>Pepys</surname><given-names>MB</given-names></name></person-group>. <article-title>Risk factors for coronary heart disease and acute-phase proteins. A population-based study</article-title>. <source>Eur Heart J</source> <year>1999</year>; <volume>20</volume>(<issue>13</issue>): <fpage>954</fpage>–<lpage>959</lpage>.</citation></ref>
<ref id="bibr27-1741826711422990"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>GW</given-names></name><name><surname>Lee</surname><given-names>TH</given-names></name><name><surname>Vilcek</surname><given-names>J</given-names></name></person-group>. <article-title>TSG-14, a tumor necrosis factor- and IL-1- inducible protein, is a novel member of the pentraxin family of acute phase proteins</article-title>. <source>J Immunol</source> <year>1993</year>; <volume>150</volume>(<issue>5</issue>): <fpage>1804</fpage>–<lpage>1812</lpage>.</citation></ref>
<ref id="bibr28-1741826711422990"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brugger-Andersen</surname><given-names>T</given-names></name><name><surname>Ponitz</surname><given-names>V</given-names></name><name><surname>Kontny</surname><given-names>F</given-names></name><name><surname>Staines</surname><given-names>H</given-names></name><name><surname>Grundt</surname><given-names>H</given-names></name><name><surname>Sagara</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>The long pentraxin 3 (PTX3): a novel prognostic inflammatory marker for mortality in acute chest pain</article-title>. <source>Thromb Haemost</source> <year>2009</year>; <volume>102</volume>(<issue>3</issue>): <fpage>555</fpage>–<lpage>563</lpage>.</citation></ref>
<ref id="bibr29-1741826711422990"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>AMW</given-names></name><name><surname>Pedersen</surname><given-names>BK</given-names></name></person-group>. <article-title>The anti-inflammatory effect of exercise</article-title>. <source>J Appl Physiol</source> <year>2005</year>; <volume>98</volume>(<issue>4</issue>): <fpage>1154</fpage>–<lpage>1162</lpage>.</citation></ref>
<ref id="bibr30-1741826711422990"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kasapis</surname><given-names>C</given-names></name><name><surname>Thompson</surname><given-names>PD</given-names></name></person-group>. <article-title>The effects of physical activity on serum C-reactive protein and inflammatory markers. A systemic review</article-title>. <source>J Am Coll Cardiol</source> <year>2005</year>; <volume>45</volume>(<issue>10</issue>): <fpage>1563</fpage>–<lpage>1569</lpage>.</citation></ref>
<ref id="bibr31-1741826711422990"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Plaisance</surname><given-names>EP</given-names></name><name><surname>Grandjean</surname><given-names>PW</given-names></name></person-group>. <article-title>Physical activity and high-sesitivity C-reactive protein</article-title>. <source>Sports Med</source> <year>2006</year>; <volume>36</volume>(<issue>5</issue>): <fpage>443</fpage>–<lpage>458</lpage>.</citation></ref>
<ref id="bibr32-1741826711422990"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tisi</surname><given-names>PV</given-names></name><name><surname>Hulse</surname><given-names>M</given-names></name><name><surname>Chulakadabba</surname><given-names>A</given-names></name><name><surname>Gosling</surname><given-names>P</given-names></name><name><surname>Shearman</surname><given-names>CP</given-names></name></person-group>. <article-title>Exercise training for intermittent claudication: does it adversely affect biochemical markers of the exercise-induced inflammatory response?</article-title> <source>Eur J Vasc Endovasc Surg</source> <year>1997</year>; <volume>14</volume>(<issue>5</issue>): <fpage>344</fpage>–<lpage>350</lpage>.</citation></ref>
<ref id="bibr33-1741826711422990"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Konig</surname><given-names>D</given-names></name><name><surname>Deibert</surname><given-names>P</given-names></name><name><surname>Winkler</surname><given-names>K</given-names></name><name><surname>Berg</surname><given-names>A</given-names></name></person-group>. <article-title>Association between LDL-cholesterol, statin therapy, physical activity and inflammatory markers in patients with stable coronary heart disease</article-title>. <source>Exerc Immunol Rev</source> <year>2005</year>; <volume>11</volume>(<issue>1</issue>): <fpage>97</fpage>–<lpage>107</lpage>.</citation></ref>
<ref id="bibr34-1741826711422990"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gielen</surname><given-names>S</given-names></name><name><surname>Adams</surname><given-names>V</given-names></name><name><surname>Linke</surname><given-names>A</given-names></name><name><surname>Erbs</surname><given-names>S</given-names></name><name><surname>Mobius-Winkler</surname><given-names>S</given-names></name><name><surname>Schubert</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Exercise training in chronic heart failure: correlation between reduced local inflammation and improved oxidative capacity in the skeletal muscle</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2005</year>; <volume>12</volume>(<issue>4</issue>): <fpage>393</fpage>–<lpage>400</lpage>.</citation></ref>
<ref id="bibr35-1741826711422990"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schumacher</surname><given-names>A</given-names></name><name><surname>Peersen</surname><given-names>K</given-names></name><name><surname>Sommervoll</surname><given-names>L</given-names></name><name><surname>Seljeflot</surname><given-names>I</given-names></name><name><surname>Arnesen</surname><given-names>H</given-names></name><name><surname>Otterstad</surname><given-names>JE</given-names></name></person-group>. <article-title>Physical performance is associated with markers of vascular inflammation in patients with coronary heart disease</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2006</year>; <volume>13</volume>(<issue>3</issue>): <fpage>356</fpage>–<lpage>362</lpage>.</citation></ref>
<ref id="bibr36-1741826711422990"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rauchhaus</surname><given-names>M</given-names></name><name><surname>Doehner</surname><given-names>W</given-names></name><name><surname>Francis</surname><given-names>DP</given-names></name><name><surname>Davos</surname><given-names>C</given-names></name><name><surname>Kemp</surname><given-names>M</given-names></name><name><surname>Liebenthal</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Plasma cytokine parameters and mortality in patients with chronic heart failure</article-title>. <source>Circulation</source> <year>2000</year>; <volume>102</volume>(<issue>25</issue>): <fpage>3060</fpage>–<lpage>3067</lpage>.</citation></ref>
<ref id="bibr37-1741826711422990"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Torre-Amione</surname><given-names>G</given-names></name></person-group>. <article-title>Immune activation in chronic heart failure</article-title>. <source>Am J Cardiol</source> <year>2005</year>; <volume>95</volume>(<issue>11A</issue>): <fpage>3C</fpage>–<lpage>8C</lpage>.</citation></ref>
<ref id="bibr38-1741826711422990"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>DJ</given-names></name><name><surname>Cleman</surname><given-names>MW</given-names></name><name><surname>Pfau</surname><given-names>SE</given-names></name><name><surname>Rollins</surname><given-names>SA</given-names></name><name><surname>Ramahi</surname><given-names>TM</given-names></name><name><surname>Mayer</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Serum complement activation in congestive heart failure</article-title>. <source>Am Heart J</source> <year>2001</year>; <volume>141</volume>(<issue>4</issue>): <fpage>684</fpage>–<lpage>690</lpage>.</citation></ref>
</ref-list>
</back>
</article>